IDH assay facilitates timelier leukemia treatment: Rong He, M.D. - Insights
In this test-specific episode of the "Answers From the Lab" podcast, Rong He, M.D., explains how Mayo Clinic Laboratories' IDHQ test improves upon next generation sequencing for assessing AML treatment options.
Enhanced detection of genetic mutation to optimize leukemia treatment - Insights
Rong He, M.D., describes how Mayo Clinic Laboratories’ NPM1Q assay detects all known forms of a genetic mutation found in about 30% of people with acute myeloid leukemia, or AML. Identifying the NPM1 mutation is critical for clinical...
Genetic Testing to Enhance Multiple Myeloma Treatment - Insights
Multiple myeloma is the second most common blood cancer, but most people haven’t heard of it until they or someone they know is diagnosed with the disease. March is Myeloma Action Month—a time to focus attention on the fight against...
Zooming in on Cancer Suspects - Insights
Genetic testing is like security-camera video footage of a break-in, providing essential clues to identify a culprit. In certain cancers, the "culprit" might be a rearrangement in a person's DNA, which genomic testing can capture. Mayo...
Direct Ethanol Biomarker Testing: PETH - Insights
Paul Jannetto, Ph.D., describes Mayo Clinic Laboratories' new direct biomarker test for alcohol consumption. PETH is a blood test with a window of detection of about two to four weeks — compared with five days for urine-based screening for...
Extended Spectrum Beta Lactamase Testing - Insights
Audrey Schuetz, M.D., provides a detailed overview of Mayo Clinic Laboratories’ new culture-based extended spectrum beta lactamase (ESBL) testing. Used to screen for the presence of multi-drug resistant gram-negative bacteria in donor stool...
Chromium and Cobalt - Insights
Paul Jannetto, Ph.D., describes Mayo Clinic Laboratories' synovial fluid testing for patients with symptoms of failed hip arthroplasty. The Food and Drug Administration recommends testing for elevated chromium and cobalt, which can indicate...
Rapid response: COVID-19, monkeypox, and whatever comes next - Insights
Mayo Clinic Laboratories' rapid response to public health threats has been honed during outbreaks of viruses like 2009’s H1N1 influenza, Zika, Ebola and, most recently, COVID-19. Before COVID-19, laboratory staff were already experts in...
PIK3CA assay guides treatment of progressing breast cancer - Insights
Katherine Geiersbach, M.D., explains how Mayo Clinic Laboratories' PIK3CA assay informs breast cancer treatment. The assay identifies patients eligible for a certain second-line therapy when initial treatment has failed.
RNA test identifies large B-cell lymphoma subtypes: Lisa Rimsza, M.D. - Insights
Lisa Rimsza, M.D., explains how Mayo Clinic Laboratories' unique PM3CX test can accurately determine subtypes of large B-cell lymphoma. Precise diagnosis is critical to choosing appropriate chemotherapy.